Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an – GlobeNewswire

by

  1. Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an GlobeNewswire
  2. AKRO Stock Plummets, Dragging Down ETNB Stock, On Liver-Disease Flop Investor’s Business Daily
  3. Stocks trending October 10, 2023: Akero Therapeutics, Palantir, Hyatt Hotels Yahoo Finance
  4. Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Yahoo Finance
  5. Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more (COHR) Seeking Alpha
  6. View Full Coverage on Google News

Read original article here

Leave a Comment